drugset / Trial / NCT07218627

A Research Study on the Effects of NNC0537-1482 in Participants With Heart Failure

NCT07218627 ↗

Phase 1 Recruiting 36 enrolled Novo Nordisk A/S
RandomizedSequentialQuadruple-blindTreatment

Summary

The study is testing a new drug (NNC0537-1482) to potentially treat people with heart failure. The purpose of the study is to see if NNC0537-1482 is safe and how it works in the body. Participants will either get NNC0537-1482 or placebo (a "dummy drug" without any active ingredients) and which treatment they get is decided by chance. This study will last up to 64 days with an additional screening period up to 28 days.

Timeline

Start
2025-10-23
Primary completion
2027-01-15
Completion
2027-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject NNC0537-1482 Unknown — Subcutaneous

Indications